Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7694265 | 1.00 | ADRB3 (0.46) | ADRB3BACE1KDM4EALDH1A1TAAR1 | |
| SCHEMBL7122412 | 1.00 | ADRB3 (0.46) | ADRB3BACE1KDM4EALDH1A1TAAR1 | |
| SCHEMBL7122414 | 0.95 | BACE1 (0.44) | ADRB3BACE1KDM4EALDH1A1TAAR1 | |
| SCHEMBL27635276 | 0.90 | GLI1 (0.46) | ADRB3BACE1KDM4EALDH1A1TAAR1 | |
| SCHEMBL19245779 | 0.90 | TAAR1 (0.46) | ADRB3BACE1KDM4EALDH1A1TAAR1 | |
| SCHEMBL12834438 | 0.89 | BACE1 (0.44) | ADRB3BACE1KDM4EALDH1A1TAAR1 | |
| SCHEMBL7120686 | 0.87 | ADRB3 (0.43) | ADRB3BACE1 | |
| SCHEMBL7993383 | 0.87 | CYP51A1 (0.46) | ADRB3BACE1 | |
| SCHEMBL7120679 | 0.87 | ADRB3 (0.43) | ADRB3BACE1 | |
| SCHEMBL17177098 | 0.85 | KCNH2 (0.45) | BACE1KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569873-B2 | Treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination | WYETH | 2003-05-27 | — | — | US | disclosed |
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| US-6465501-B2 | USEFUL IN TREATING OR INHIBITING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA, ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, GLAUCOMA, OCULAR HYPERTENSION AND INCONTINENCE | WYETH | 2002-10-15 | — | — | US | disclosed |
| US-20020032222-A1 | Azolidines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | ADRB3 3/4885BACE1 396/4885KDM4E 4172/4885 |
| US-20020032222-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | ADRB3 3/4885BACE1 396/4885KDM4E 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.